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Perfluorooctanesulfonate [PFOS;
CF3(CF2)7SO3
–] and its acid salts were
derived from perﬂuorooctanesulfonyl ﬂuoride
[POSF; CF3(CF2)7SO2F]. Major product
applications were developed using POSF
through formation of N-alkylsulfonamides
that were used in surfactants, paper and pack-
aging treatments, and surface protectants
(e.g., carpet, upholstery, textiles). Depending
on the specific functional derivitization or
polymerization, these POSF-based products
may have degraded or metabolized, to an
undetermined degree, to PFOS, a stable and
persistent end product that has a widespread
presence in the general population (Butenhoff
et al. 2006) and wildlife (Houde et al. 2006).
Salts of perﬂuorooctanoic acid, in particular
ammonium perﬂuorooctanoate (APFO), have
been used as surfactants and processing aids in
the production of ﬂuoropolymers and ﬂuoro-
elastomers. Industrial production of the salts of
perﬂuorooctanoic acid occur through electro-
chemical fluorination and telomerization.
Perfluorooctanoate [PFOA; CF3(CF2)6COO–],
the dissociated carboxylate anion, has been
measured in humans worldwide but generally
at lower nanogram per milliliter concentrations
than PFOS (Houde et al. 2006). 
In rats, PFOS and PFOA are not metabo-
lized and enter into the enterohepatic circula-
tion (Johnson et al. 1984; Kemper 2003;
Kuslikis et al. 1992; Vanden Heuvel et al.
1991). Because of the stability of the carbon–
ﬂuorine bond and the high electronegativity of
perﬂuorinated alkyl acids, metabolism would
not be favored; thus, perﬂuorohexanesulfonate
(PFHS) is also not expected to be metabolized.
Based on the determination of volumes of
distribution from single-dose intravenous stud-
ies in cynomolgus monkeys, the distributions
of PFOS, PFHS, and PFOA are primarily
extracellular (Butenhoff et al. 2004; Noker
and Gorman 2003a, 2003b). Kerstner-Wood
et al. (2003) found PFOS, PFHS, and PFOA
to be highly bound in rat, monkey, and
human plasma over a concentration range of
1–500 µg/mL. When incubated with human
plasma protein fractions, all three compounds
were highly bound (99.7 to > 99.9%) to albu-
min, and showed affinity for β-lipoproteins
(95.6, 64.1, and 39.6% for PFOS, PFHS, and
PFOA, respectively). Some binding to α- and
γ-globulin fractions and minor interactions
with transferrin (PFHS and PFOA) were also
noted. PFOS and PFOA have been shown to
compete for fatty acid binding sites on liver
fatty acid binding protein, with PFOS giving
the stronger response (Luebker et al. 2002).
The elimination rates of PFOS and PFHS
have been studied in male and female
cynomolgus monkeys after intravenous dosing
(Noker and Gorman 2003a, 2003b) and for
PFOS after repeated oral dosing (Seacat et al.
2002). Noker and Gorman (2003a, 2003b)
reported mean (± SD) terminal elimination
half-lives, ranging from 88 to 146 days (132 ±
13 days for males and 110 ± 26 days for
females) for PFOS and 49 to 200 days (141 ±
52 days for males and 87 ± 47 days for
females) for PFHS, after intravenous dosing of
three male and three female cynomolgus mon-
keys in separate experiments, with no signiﬁ-
cant difference between males and females or
between the two compounds. Seacat et al.
(2002) reported an approximate terminal
elimination half-life of 200 days for PFOS in
male and female cynomolgus monkeys dur-
ing 1 year immediately following 6 months
of daily oral dosing with either 0.15 or
0.75 mg/kg PFOS.
Elimination rates in species other than the
monkey have been determined for PFOS and
PFOA. Within 89 days after a single intra-
venous dose of 14C-PFOS, 30% of the 14C
was excreted in the urine and 12% in the feces
of male rats (Johnson et al. 1979). For PFOA,
significant interspecies differences have been
observed (Hundley et al. 2006; Kudo and
Kawashima 2003), and differential expression
of organic anion transporters in renal proxi-
mal tubule cells have been suggested as an
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BACKGROUND: The presence of perﬂuorooctanesulfonate (PFOS), perﬂuorohexanesulfonate (PFHS),
and perﬂuorooctanoate (PFOA) has been reported in humans and wildlife. Pharmacokinetic differ-
ences have been observed in laboratory animals.
OBJECTIVE: The purpose of this observational study was to estimate the elimination half-life of
PFOS, PFHS, and PFOA from human serum. 
METHODS: Twenty-six (24 male, 2 female) retired ﬂuorochemical production workers, with no addi-
tional occupational exposure, had periodic blood samples collected over 5 years, with serum stored in
plastic vials at –80°C. At the end of the study, we used HPLC-mass spectrometry to analyze the
samples, with quantiﬁcation based on the ion ratios for PFOS and PFHS and the internal standard
18O2-PFOS. For PFOA, quantitation was based on the internal standard 13C2-PFOA. 
RESULTS: The arithmetic mean initial serum concentrations were as follows: PFOS, 799 ng/mL
(range, 145–3,490); PFHS, 290 ng/mL (range, 16–1,295); and PFOA, 691 ng/mL (range,
72–5,100). For each of the 26 subjects, the elimination appeared linear on a semi-log plot of con-
centration versus time; therefore, we used a ﬁrst-order model for estimation. The arithmetic and
geometric mean half-lives of serum elimination, respectively, were 5.4 years [95% conﬁdence inter-
val (CI), 3.9–6.9] and 4.8 years (95% CI, 4.0–5.8) for PFOS; 8.5 years (95% CI, 6.4–10.6) and
7.3 years (95% CI, 5.8–9.2) for PFHS; and 3.8 years (95% CI, 3.1–4.4) and 3.5 years (95% CI,
3.0–4.1) for PFOA. 
CONCLUSIONS: Based on these data, humans appear to have a long half-life of serum elimination of
PFOS, PFHS, and PFOA. Differences in species-speciﬁc pharmacokinetics may be due, in part, to a
saturable renal resorption process.
KEY WORDS: biomonitoring, perﬂuoroalkyl acids, perﬂuorohexanesulfonate, perﬂuorooctanesulfonate,
perﬂuorooctanoate, PFHS, PFOA, PFOS, pharmacokinetics. Environ Health Perspect 115:1298–1305
(2007). doi:10.1289/ehp.10009 available via http://dx.doi.org/ [Online 12 June 2007]explanation for sex differences in the rat
(Kudo et al. 2002) and low elimination rates
in humans (Andersen et al. 2006).
The purpose of the present study was to
estimate the serum elimination half-life of
PFOS, PFHS, and PFOA in humans through
the long-term follow-up of retired fluoro-
chemical production workers. Although these
retirees were no longer occupationally
exposed, their serum concentrations were
expected to be considerably higher than those
of the general population. 
Materials and Methods
Study population. Retirees from the 3M
Company, Decatur, Alabama, facility were eli-
gible for the study if they had retired between
January 1995 and onset of the study in
November 1998. The retirees were invited to
participate based on having prior work assign-
ments in ﬂuorochemical production. Thirty-
four individuals were identified and 24
(22 males, 2 females) agreed to participate
(71%). In addition, 3 retirees from the 3M,
Cottage Grove, Minnesota, chemical division
were also directly invited to participate. Their
primary exposure would have occurred in the
APFO production area. The study was
approved by the 3M Institutional Review
Board. All study participants gave informed
consent before study initiation. Participation
was voluntary and subjects could withdraw
from the study at any time, although none did.
Participants received $50 per blood collection.
Blood collection (approximately 10 mL/
collection) for the 24 Decatur retirees began in
November 1998, with subsequent collections
for each employee in June and November
1999, May 2000, February 2001, January
2002, January 2003, and March 2004. Blood
collections almost always occurred on the same
day for all of the retirees. Maximum follow-up
was 1,945 days (5.3 years). Blood collection for
the 3 Cottage Grove participants began in June
1999 and ended in March 2004, with five
additional blood collections interspersed
between these dates. For these 3 retirees,
blood collections were generally not on the
same day but within a short (1–2 weeks)
period of time. Maximum follow-up was
1,744 days (4.8 years). 
Serum was stored in plastic vials at –80°C.
All samples for PFOA analysis were analyzed
in batches of 30 samples/day at the end of the
study. Samples for PFHS and PFOS were ana-
lyzed separately from PFOA samples.
Laboratory analysis. Chemicals. Potassium
salt of PFOS, potassium salt of PFHS, and
ammonium salt of PFOA were obtained from
internal sources at the 3M Company (St. Paul,
MN). The internal standard for PFOS and
PFHS analyses was a labeled perﬂuorooctane-
sulfonate (18O2-PFOS) obtained from the
Research Triangle Institute (Research Triangle
Park, NC). For PFOA, we used a labeled
13C2-PFOA (DuPont de Nemours & Co.,
Wilmington, DE) as the internal standard.
The acetonitrile and methanol used for extrac-
tion purposes were “Distilled in Glass” grade
solvents from Burdick and Jackson (Morris
Township, NJ). Reagent grade formic acid,
reagent grade potassium hydroxide, ammo-
nium acetate, and ammonium sulfate were
obtained from J.T. Baker (Phillipsburg, NJ).
The ammonium sulfate was washed with
methanol and dried before use. All other
chemicals and solvents were used without fur-
ther puriﬁcation. 
Standard solutions and quality control
materials. We adjusted the initial weights of
the primary standards for impurities and the
salts present such that the concentrations in
methanol represented the negative ion con-
centrations as measured in the serum matrix
analyzed. Stock standard solutions were pre-
pared in methanol at concentrations of
0.1 mg/mL; separate stock standards were
prepared (0.1 mg/mL) in methanol for spik-
ing control materials; and additional standard
dilutions were completed in methanol as
required for spiking into the standard curve
matrices. Rabbit or calf serum controls were
spiked at target concentrations in bulk to
cover the range of the assay as completed. The
quality control solutions were placed on a
magnetic stirrer overnight to mix thoroughly,
and aliquots were frozen at –80°C until use.
Blank rabbit or calf serum was evaluated with
each run, and the spiked matrix was used for
matrix-matched standard curve extractions. 
Both intrabatch and interbatch run accu-
racy and precision measurements were per-
formed. For PFOA, we used three spiked
samples with targeted means of 80, 240, and
750 ng/mL. Recovered means ranged between
93.3 and 101.5%. Coefficients of variation
(CVs) ranged between 1.4 and 3.8. For PFOS
and PFHS, we used 80 and 350 ng/mL
targeted mean spiked samples. For PFOS,
recovered means ranged between 91.0 and
99.7%, with CVs between 2.2 and 4.9.
For PFHS, recovered means ranged between
88.6 and 105.2%, with CVs ranging between
6.9 and 11.9.
The lower limit of quantitation (LOQ)
was set as the lowest acceptable standard value
fitted on the standard curves used. For all
analyses, regardless of instrumentation used,
the lower limit of quantitation was 10.0
ng/mL. PFOA was analyzed using the
Finnigan TSQ 7000 instrument (Thermo
Electron Corp., Waltham, MA) using the
parent negative ions (Q1 MS) only. Based on
a signal-to-noise ratio of 5:1, the lower limit
of detection for PFOA was 1.6 ng/mL. PFOS
and PFHS were analyzed using the API 4000
instrument (Applied Biosystems, Foster, CA)
used in the tandem mass spectrometry
(MS-MS) mode. Based on a signal-to-noise
ratio of 5:1, the lower limit of detection was
1.0 ng/mL for PFOS and was 0.5 ng/mL for
PFHS.
Sample extraction. Initial extractions were
completed at an acidic pH coupled with an
alkaline back extraction technique. All primary
extraction tubes were new, disposable poly-
propylene tubes to which an appropriate
amount of internal standard was added before
the initial extraction. The initial extraction
was based on 250 µL serum, 300 µL 1.0 N
formic acid, and 300 µL saturated ammonium
sulfate added together in the primary extrac-
tion tube. The tubes were then brieﬂy mixed
by vortexing for 30 sec. The primary extrac-
tion solvent was acetonitrile (5 mL). After the
addition of the acetonitrile, all tubes were
shaken on a mechanical shaker for 30 min.
The primary extraction tubes were removed
from the shaker and centrifuged at 2,500 × g.
The top layer (acetonitrile) containing the
compounds of interest (analytes and internal
standard) was decanted to a clean, labeled tube
and the acetonitrile was dried down to residual
aqueous using the LabConCo evaporator
(LabConCo, Kansas City, MO). 
Back extraction. Residual aqueous from
the primary extraction was further diluted
with 300 µL deionized water and made alka-
line with the addition of 300 µL of 1.0 N
potassium hydroxide solution. This mixture
was then vortexed and re-extracted (alkaline
back extraction) using 7.0 mL methyl tert-
butyl ether (MTBE) on a mechanical shaker
for 20 min. After centrifugation at 2,500 × g
for 5 min, the top layer (MTBE) was trans-
ferred to a clean polypropylene tube for sol-
vent evaporation using a gentle stream of
nitrogen gas in a temperature-controlled water
bath (N-EVAP; Organomation Associates
Inc., Berlin, MA).
The tubes were promptly removed after
the MTBE solvent had evaporated to dryness.
Samples were then reconstituted using 400 µL
of solution containing 2 mM ammonium
acetate (50%) and acetonitrile (50%). After
vortexing, the mobile phase mixture was trans-
ferred to polypropylene microliter inserts.
These inserts were then placed in a 2-mL glass
microvial, capped, and placed on either the
API 4000 liquid chromatography-MS-MS sys-
tem or the TSQ 7000 for analysis. 
HPLC conditions. Both the TSQ 7000
and the API 4000 instruments were equipped
with identical high-performance liquid chro-
matography (HPLC) columns. We used
MacMod (Chadds Ford, PA) ACE C-18
columns (100 × 2.1 mm i.d. columns, 5-µm
particle size). A 3-µm guard column was used
in front of the analytical column (10 × 2.1
mm i.d.). The TSQ 7000 ﬂow rates were opti-
mized for an isocratic separation of the
branched chain isomers for the PFOA analysis
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phase composition was approximately 50%
acetonitrile and 50% 2 mM ammonium
acetate. A 5-µL injection was employed to
introduce the sample to the TSQ 7000 mass
spectrometer. 
The liquid chromatograph used with the
API 4000 system was the Agilent 1100 series
HPLC system (Santa Clara, CA). The API
4000 instrument was operated with a flow
rate of 0.35 mL/min, using a mobile phase
mixture similar to that used in the analysis of
PFOA as described above.
LC-MS analysis. PFOA analysis was com-
pleted using a TSQ-7000 mass spectrometer
operating in Q1 (parent ion) mode. PFOS
and PFHS analyses were completed simultane-
ously using an API 4000 mass spectrometer
operating in multiple reaction–monitoring
(product ion) mode. PFOS and PFHS extracts
were reevaluated for all samples using the
TSQ-7000 (parent ion) for both validations of
the new instrument and to justify choosing
the product ion at 80 amu for quantitation. 
PFOS and PFHS each form product ions
at 80 and 99 amu, and both product ions were
monitored during this study. Quantitation
was based on the area ratio between the
80-amu product ion formed by the analytes
and the internal standard (
18O2-PFOS) prod-
uct ion formed at 84 amu. Quantitation of the
PFOS using the TSQ 7000 was completed on
the 499-amu ion for PFOS, the 399-amu ion
formed for PFHS, and the 503-amu ion
formed for the 18O2-PFOS internal standard
ion. PFOA was completed based on the for-
mation of the electrospray negative ions
formed at 413 amu and the negative ion
formed from 
13C2-PFOA at 415 amu.
The TSQ 7000 system was operated in the
electrospray ionization mode using negative
ionization detection with a constant source
potential of 3.0 kV applied. The following
masses were monitored for peak intensities
[base peak (Q1 mass m/z)]: PFOA (413.0);
PFOA internal standard, C6F15
13C2OO–
(415.0); PFOS (499.0); PFOS internal stan-
dard, C8F17S18O2 O– (503.0); and PFHS
(399.0). 
The TSQ 7000 capillary inlet heater was
held at a constant 300°C. PFOA quantitative
calculations were based on the ion ratios
between PFOA and the added internal stan-
dard (C6F15
13C2OO–). PFOS and PFHS
quantitative calculations were based on the
ion ratios between the compounds of interest
(PFOS, PFHS) and the added internal stan-
dard (C8F17S18O2O–). Linear regression
analysis was then cmpleted with standards
weighted at 1/x. Concentration was plotted
along the x-axis and the peak area ratio was
plotted on the y-axis.
The API 4000 system was operated in the
negative ion mode using TurboIon spray
operation. All API 4000 source parameters
were optimized according to the manufac-
turer’s guidelines. The speciﬁc ions monitored
were base peak Q1 (mass m/z); Q3 mass
(product ions m/z): PFOS (Q1, 499.0; Q3, 80
and 99); PFOS internal standard (Q1, 503.0;
Q3, 84 and 103); and PFHS (Q1, 399.0; Q3,
80 and 99).
LC-MS instrument data analysis. Data
acquisition and analysis were completed for all
blanks, standards, quality control samples, and
unknowns using Analyst software on the API
4000 or the Excalibur software package on the
TSQ 7000. Manual integration of isomer
peaks was completed only where necessary to
include the area under the branched isomers
present as part of the total peak area integrated.
No branched PFOA isomer peak was measur-
able when compared with the low standard at
10 ng/mL. However, using a lower detection
limit resulted in branched PFOA concentra-
tions of approximately 1% (range, 0.1–6.0%).
The PFOA standard contained the linear iso-
mer at 78% and the combined branched chain
isomers at 22%. Linear regression calibration
curves weighted by the reciprocal of the stan-
dard amount (1/x) were used for quantitation. 
Data analysis. During the review of the
subjects’ questionnaire data, we determined
that three Decatur retirees likely had additional
occupational exposure after their initial blood
collection in November 1998. One retiree had
Olsen et al.
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Table 1. Demographic characteristics of study participants by subject number.
No. Years retired Age at initial
Subject years at initial collection Days Years Samples
no. Sex Facility Usual job category worked collection (years) followed followed analyzed
1 Male Decatur Laboratory/technician 32 0.6 59 1,945 5.3 8
2 Male Decatur Supervisor 30 2.1 62 551 or 1,945a 2.2 or 5.3a 4 or 8a
3 Male Decatur Supervisor 27 3.1 65 1,730 or 1,945b 4.7 or 5.3b 7 or 8b
4 Male Decatur Maintenance 33 3.7 61 1,945 5.3 8
5 Male Cottage Grove Chemical operator 28 11.5 75 1,730 4.7 7
6 Male Decatur Cell operator 29 1.9 63 1,945 5.3 8
7 Female Decatur Chemical operator 20 2.5 65 1,945 5.3 8
8 Male Decatur Maintenance 29 3.5 59 1,945 5.3 8
9 Male Decatur Foreman 36 1.9 60 1,139c 3.1 4
10 Male Decatur General worker 35 1.9 57 1,945 5.3 8
11 Male Decatur Maintenance 27 0.9 64 1,945 5.3 8
12 Male Cottage Grove Foreman 36 7.5 64 1,730 4.7 7
13 Male Decatur Laboratory/technician 36 1.9 59 1,945 5.3 8
14 Male Decatur Laboratory/technician 32 0.9 59 1,945 5.3 8
15 Male Decatur Cell operator 30 2.9 63 1,945 5.3 8
16 Male Decatur Foreman 35 1.9 58 1,945 5.3 8
17 Male Decatur Maintenance 33 1.9 59 1,945 5.3 8
18 Male Decatur Maintenance 21 1.0 63 1,524d 4.2 6
19 Male Decatur Laboratory/technician 33 1.1 59 1,945 5.3 8
20 Male Decatur Foreman 34 1.5 58 1,524d 4.2 7
21 Male Decatur General worker 30 0.9 56 1,730e 4.7 7
22 Male Decatur Cell operator 33 1.2 58 1,945 5.3 8
23 Male Decatur Foreman 34 3.1 59 1,945 5.3 8
24 Male Cottage Grove Chemical operator 36 7.5 65 1,744 4.8 7
25 Female Decatur Chemical operator 22 0.4 55 1,945 5.3 8
26 Male Decatur Chemical operator 31 0.9 61 1,945 5.3 8
aPFHS samples were < LOQ after 551 days; therefore, analyses included only 4 samples (> LOQ). All PFOS and PFOA samples were > LOQ; therefore, analyses included 8 samples collected
through 1,945 days. bInitial sample was analyzed only for PFOA because insufﬁcient sample remained to analyze for all three compounds due to prior interim analyses. Therefore, follow-up
was 1,730 days for PFOS and PFHS (7 samples) and 1,945 days for PFOA (8 samples). cSubject had potential for occupational exposure through day 806 in study; therefore, we included only
the last 1,139 days of follow-up, with 4 samples analyzed. dSubject died during study collection period; the 1,524 days follow-up included 6 samples analyzed for subject 18, and 7 samples
analyzed for subject 20. eSubject had potential for occupational exposure through day 215 of study; therefore, follow-up included last 1,730 days, with 7 samples analyzed.intermittently worked with ﬂuorochemicals at
the Decatur facility throughout the study
period. This retiree was excluded from the
entire data analysis. A second Decatur retiree
had intermittently worked in the Decatur
facility until February 2001; therefore, his
data were truncated until that point in time.
A third Decatur retiree likely had occupa-
tional exposure to PFOA between his initial
(November 1998) and second (June 1999)
blood collections that affected his assessment;
therefore, we used June 1999 as his initial
time point for measurement of PFOA. All
other subjects had all of their data analyzed.
The 26 retirees had 197 blood collections
included for half-life analyses. A total of 189
(96%) of the 197 blood collections had sufﬁ-
cient sample available for split analyses.
Spearman Rho correlations exceeded 0.98 for
each analyte. 
We used WinNonlin software, version 4.1
(Pharsight Corporation, Mountain View, CA)
to calculate the half-life of elimination based
on the mean value of the split analyses. The
data were linear when plotted as the logarithm
of serum concentration versus time. Therefore,
we assumed a ﬁrst order model (Medinsky and
Klaassen 1996).
We used multiple regression to determine
statistically signiﬁcant (p < 0.05) associations
between the half-life of elimination for PFOS,
PFHS, and PFOA and explanatory variables
including initial and end-of-study perﬂuoro-
chemical concentration, age at study onset,
years worked, and years since retirement. 
Results
Table 1 presents the demographic information
of the 26 subjects by ascending order of their
initial serum PFOS concentration as shown in
Table 2. At the time of the initial blood collec-
tion, the mean age of the 26 subjects was
61 years (range, 55–75 years). These subjects
had worked a mean of 31 years (range, 20–36
years), and they had been retired on average
2.6 years (range, 0.4–11.5 years). Based on
their work history records, their lifetime usual
jobs at either the 3M Decatur or Cottage
Grove facility were categorized as electrochemi-
cal ﬂuorination cell operators (n = 3), chemical
operators (n = 6), maintenance workers (n = 5),
foremen (n = 6), laboratory technicians (n = 3),
and other (n = 2: warehouseman and engi-
neer). Their mean length of study follow-up
was 1,849 days (range, 1,139–1,945 days)
equivalent to a mean of 5.0 years (range,
3.1–5.3 years). Two of the retired subjects died
during the study follow-up period, which lim-
ited each of their length of follow-up to
1,524 days (4.2 years).
Based on the individual data presented in
Table 2, the arithmetic mean initial serum
concentrations were as follows: PFOS,
799 ng/mL (median, 626 ng/mL; range,
145–3,490 ng/mL); PFHS, 290 ng/mL
(median, 193 ng/mL; range, 16–1,295
ng/mL); and PFOA, 691 ng/mL (median,
408 ng/mL; range, 72–5,100 ng/mL). The
arithmetic mean end-of-study serum concen-
trations were PFOS, 403 ng/mL (median
295 ng/mL; range, 37–1,740 ng/mL); PFHS,
182 ng/mL (median 117 ng/mL; range
10–791 ng/mL); and PFOA, 262 ng/mL
(median 148 ng/mL; range 17–2,435 ng/mL). 
We examined semi-log plot graphs of
concentration by time for each of the 26 sub-
jects (Figure 1). Individual serum elimination
half-lives for PFOS, PFHS, and PFOA using
a ﬁrst order model are presented in Table 2.
Assuming a log-normal distribution, Pearson
correlation coefficients for the log half-lives
(days) of serum elimination were r = 0.72
(p < 0.0001) for PFOS and PFOA; r = 0.65
(p = 0.0003) for PFOS and PFHS; and
r = 0.46 (p = 0.02) for PFOA and PFHS. 
Table 3 shows arithmetic and geometric
means and their respective 95% confidence
intervals (CIs) for the serum elimination half-
lives of PFOS, PFHS, and PFOA. The arith-
metic mean half-lives of elimination for PFOS,
PFHS, and PFOA were 5.4 years (95% CI,
3.9–6.9), 8.5 years (95% CI, 6.4–10.6), and
3.8 years (95% CI, 3.1–4.4), respectively.
Median values and ranges are also reported in
Table 3 and indicate the right skewness of the
distribution, as visualized in Figure 2.
Excluding subjects 19 and 24, the two subjects
with the highest half-lives of serum elimination
for PFOS and PFHS that appear in Figure 2,
the arithmetic mean half-lives of elimination
for PFOS and PFHS reduced to 4.8 years
(95% CI, 4.1–5.4) and 7.8 years (95% CI,
6.3–9.3), respectively. These arithmetic mean
values were then similar to the geometric mean
and median values reported in Table 3 when
each of these subjects was included in the
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Table 2. Initial and ﬁnal concentration and half-life of elimination in serum for PFOS, PFHS, and PFOA (ng/mL) by subject number.
PFOS PFHS PFOA
Subject Initial Final Half-life Initial Final Half-life Initial Final Half-life 
no. conc. conc. Days SE Years conc. conc. Days SE Years conc. conc. Days SE Years
1 145 70 1,598 203 4.4 63 27 1,440 336 3.9 74 26 1,297 86 3.6
2 156 37 885 38 2.4 16 10 798 208 2.2 72 17 830 67 2.3
3 218 82 1,411 152 3.9 58 29 4,373 4,387 12.0 490 129 1,031 63 2.8
4 258 74 1,124 65 3.0 86 37 1,971 436 5.4 142 51 1,314 151 3.6
5 259 148 2,304 265 6.3 157 110 3,508 789 9.6 1,077 404 1,205 66 3.3
6 323 129 1,273 141 3.5 647 424 2,284 463 6.3 430 108 858 49 2.3
7 443 242 1,792 203 4.9 114 86 4,458 1,599 12.2 1,622 577 1,221 80 3.3
8 477 187 1,436 57 3.9 193 113 2,347 245 6.4 306 188 2,518 195 6.9
9 545 424 2,761 749 7.6 54 48 5,329 2,978 14.6 254 150 1,401 168 3.8
10 551 207 1,387 65 3.8 191 96 1,923 186 5.3 131 45 1,107 107 3.0
11 572 296 1,961 121 5.4 60 27 1,878 260 5.1 247 104 1,551 87 4.2
12 617 226 1,163 64 3.2 302 160 1,892 253 5.2 1,180 145 561 37 1.5
13 620 249 1,354 76 3.7 191 121 3,028 370 8.3 181 65 1,280 71 3.5
14 632 213 1,224 99 3.4 149 44 1,065 145 2.9 183 50 1,020 81 2.8
15 691 391 2,456 296 6.7 494 365 4,000 934 11.0 356 244 3,334 641 9.1
16 766 383 1,871 125 5.1 373 195 2,266 170 6.2 167 78 1,737 241 4.8
17 846 430 2,464 526 6.7 273 161 3,836 1,708 10.5 212 84 1,385 142 3.8
18 924 293 908 110 2.5 269 99 1,024 1,428 2.8 390 61 570 48 1.6
19 929 802 7,919 3,126 21.7 131 102 4,939 2,036 13.5 496 284 2,552 214 7.0
20 1,033 500 1,484 56 4.1 398 256 2,825 1,173 7.7 702 248 1,041 72 2.9
21 1,079 500 1,737 349 4.8 252 144 2,134 595 5.8 549 235 1,479 208 4.0
22 1,090 478 1,566 85 4.3 928 610 3,637 776 10.0 474 162 1,235 29 3.4
23 1,190 539 1,723 137 4.7 293 154 1,983 108 5.4 425 162 1,358 69 3.7
24 1,420 1,003 3,122 287 8.5 364 361 9,858 6,962 27.0 5,100 2,435 1,662 69 4.6
25 1,500 839 2,475 225 6.8 193 164 4,866 1,428 13.3 883 266 1,223 107 3.3
26 3,490 1,740 1,973 114 5.4 1,295 791 3,180 680 8.7 1,833 486 1,061 72 2.9
conc., concentration.analyses. The two female subjects (subjects 7
and 25) had arithmetic mean serum elimina-
tion half-lives similar to those calculated for
males, respectively, for PFOS (5.9 years vs. 5.4
years; p = 0.87) and PFOA (3.3 years vs. 3.8
years; p = 0.69), and non-signiﬁcantly higher
for PFHS (12.8 years vs. 8.2 years; p = 0.23). 
Positive Pearson correlation coefficients
were observed for the log transformations of the
half-life (days) of elimination for PFOS and ini-
tial (r = 0.36; p = 0.07) and end-of-study PFOS
concentrations (r = 0.60; p = 0.001). For
PFHS, the Pearson correlation coefﬁcients were
0.27 (p = 0.18) and 0.46 (p = 0.02), respec-
tively. Similarly for PFOA, the Pearson correla-
tion coefﬁcients were –0.04 (p = 0.86) and 0.31
(p = 0.12). Age at study onset, time worked,
usual 3M job, and time since retirement were
not associated with PFOS, PFHS, or PFOA
serum elimination half-lives. A review of each
subject’s self-reported diseases and medica-
tions did not provide additional evidence of
possible associations with the half-lives of
serum elimination. No renal diseases were
reported by the 26 subjects. One individual
reported an incidence of hepatitis during the
5-year study period. 
Olsen et al.
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Retirees were the population of choice for this
study for three important reasons: a) to mini-
mize the possibility of occupational exposure
as compared to a working population poten-
tially exposed to these perﬂuoroalkyl acids and
their salts; b) to have serum concentrations
higher than the general population in order to
minimize any inﬂuence that nonoccupational
sources of exposure might have on the deter-
mination of the serum elimination rate; and
c) to have serum concentrations sufficiently
measurable over time to mitigate any method-
ologic issues regarding evaluation of trend data
in the presence of detection limits.
It is unlikely that the potential for non-
occupational exposures substantially distorted
the elimination rates calculated as median
end-of-study concentrations for PFOS
(295 ng/mL), PFHS (117 ng/mL), and PFOA
(148 ng/mL), which remained above compara-
ble estimates of 30.4, 2.1, and 5.2 ng/mL,
respectively, reported for a statistically repre-
sentative sample of the U.S. general population
(Calafat et al. 2007). Furthermore, only four
study subjects (subjects 1–4) had end-of-study
PFOS concentrations that were below the
Half-life of perfluoroalkyl acids in humans
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Table 3. Measures of central tendency for half-life of serum elimination for PFOS, PFHS, and PFOA for 26 retired ﬂuorochemical production workers.
Days Years
Fluorochemical Arithmetic mean (95% CI) GM (95% CI) Median Range Arithmetic mean (95% CI) GM (95% CI) Median Range
PFOS 1,976a (1,434–2,517) 1,751 (1,461–2,099) 1,661 885–7,919 5.4a (3.9–6.9) 4.8 (4.0–5.8) 4.6 2.4–21.7
PFHS 3,109b (2,348–3,870) 2,662 (2,112–3,355) 2,586 798–9,858 8.5b (6.4–10.6) 7.3 (5.8–9.2) 7.1 2.2–27.0
PFOA 1,378 (1,131–1,625) 1,273 (1,083–1,495) 1,257 561–3,334 3.8 (3.1–4.4) 3.5 (3.0–4.1) 3.4 1.5–9.1
GM, geometric mean.
aIf subject 19 is excluded as a potential high outlier for PFOS (Figure 2), the arithmetic mean half-life = 1,738 days (95% CI, 1,497–1,979) or 4.8 years (95% CI, 4.1–5.4). bIf subject 24 is
excluded as potential high outlier for PFHS (Figure 2), the arithmetic mean half-life = 2,839 days (95% CI, 2,297–3,381) or 7.8 years (95% CI, 6.3–9.3).
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Figure 1. Semi-log plots of PFOS, PFHS, and PFOA concentrations by time (days) for subjects 1–26. Data points indicate observed values and the line shows predicted
value.Olsen et al.
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upper 95% CI of the geometric mean of the
95th percentile as reported by Calafat et al.
(97.5 ng/mL). Subject 1 had an end-of-study
concentration at the upper 95% confidence
limit of the geometric mean of the 95th per-
centile for PFHS (10 ng/mL), and no subject
was below this upper bound for PFOA
(13.5 ng/mL). It is possible that the rate of
elimination may have resulted in more shallow
slopes as concentrations declined because of
the inﬂuence of environmental exposure.
The actual pharmacokinetics of PFOS,
PFHS, and PFOA in humans is not likely to
be consistent with a one-compartment distrib-
ution in spite of the present data ﬁt to a ﬁrst
order model. Andersen et al. (2006) showed
that intravenous dosing with PFOS or PFOA
in cynomolgus monkeys produced time-
course curves consistent with a two-compart-
ment (tissue and renal filtrate) distribution.
Nevertheless, the present study data strongly
indicate that humans are very slow eliminators
of these three perfluoroalkyl acids compared
with other species. 
The serum elimination half-life of PFOA
in the present study’s 26 retired ﬂuorochemi-
cal production workers is considerably longer
than the elimination half-life in cynomolgus
monkeys (approximately 14–40 days) after
either repeated daily oral doses or a single
intravenous injection (Butenhoff et al. 2004).
Beagle dogs (Hanijärvi et al. 1988) and mice
(Hundley et al. 2006) were found to have
serum elimination half-lives of PFOA in the
same range as monkeys. Both sexes of rabbits,
however, excreted PFOA with elimination
half-lives in hours (Hundley et al. 2006). In
the rat, not only is the elimination half-life of
PFOA shorter than that in monkeys and
humans, but a notable sex difference exists
(Kemper 2003; Kudo et al. 2002; Vanden
Heuval et al. 1991). Whereas α-2u-globulin
was ruled out as a cause for the slower elimina-
tion in male rats (Han et al. 2004), the marked
difference between sexes in rats could be attrib-
utable to sex hormone regulation of the expres-
sion of certain organic anion transporters
[OAT2 (Slc22a7), OAT3 (Slc22a8), and
oatp1 (Slco1a1)] in the kidney (Kudo et al.
2002). Kudo et al. (2002) reported OAT2
(Slc22a7) to be more highly expressed in
female rat kidney and subject to up-regulation
by estradiol. 
The diversity of proximal tubular organic
anion transporters and potential for genetic
variation (Eraly et al. 2004; Kudo et al. 2002;
Ljubojevic et al. 2004) have indicated that the
long elimination half-life in humans com-
pared with that in other species may be due to
differential expression of organic anion trans-
porters and could be linked to either low-level
transport into urine or increased tubular
resorption. Harada et al. (2005) reported sex-
independent renal clearances in humans that
were 10–5-fold lower than the glomerular ﬁl-
tration rate indicating a signiﬁcant absence of
active renal excretion of PFOS and PFOA.
Using a physiologically motivated pharmaco-
kinetic model for renal clearance, Andersen
et al. (2006) described the cynomolgus mon-
key pharmacokinetic data for PFOS (Noker
and Gorman 2003a; Seacat et al. 2002) and
PFOA (Butenhoff et al. 2002, 2004) in terms
of renal resorption via high efficiency trans-
porters. Although specific transporters were
not identified, Andersen et al. (2006) con-
cluded from their model simulations that sat-
urable, high-affinity resorption processes
govern the kinetics of PFOS and PFOA, and
likely other perﬂuoroalkyl acids (e.g., PFHS),
which could account for the varied half-lives
of elimination across species. In their models,
PFOS had a higher transport capacity and
lower afﬁnity than PFOA.
In the present study, the observation that
linear PFOA is the predominant isomer in
these retired workers may also indicate
pharmacokinetic differences in either prefer-
ential lack of absorption and/or increased
elimination of branched isomers of PFOA.
This observation is supported by Loveless
et al. (2006) who reported that branched
APFO dosages administered orally to rats
resulted in considerably lower serum PFOA
concentrations compared with the same
dosages (3, 10, and 30 mg/kg/day) of 100%
linear or an 80% linear/20% branched mix-
ture of APFO, although additional differences
could also be attributable to variation in iso-
mer absorption in the gastrointestinal tract. In
mice, PFOA concentrations were similar
regardless of the same three isomer types of
APFO material and six dosages administered.
Lau et al. (2005) reported that the terminal
serum half-life of PFOA in mice was in the
range of 15–20 days, with no sex-dependent
differences in elimination.
It is also possible that differences in biliary
excretion and gut resorption could account,
in part, for the longer elimination half-life in
humans because of the enterohepatic circula-
tion observed (Johnson et al. 1984; Vanden
Heuvel et al. 1991). However, in light of the
recent evidence presented by Andersen et al.
(2006), enterohepatic circulation is likely a
lesser explanation. 
Less is known about the elimination
kinetics of PFHS in other species. The results
indicate the human half-life of serum elimina-
tion may be longer and more variable than
that of PFOS. A greater degree of variability
has also been observed for PFHS compared
with PFOS in intravenous dosing studies of
cynomolgus monkeys (Noker and Gorman
2003a; 2003b). The half-life of serum elimi-
nation for PFHS ranged between 100 and 200
days (mean, 141 days) in three male monkeys
and between 49 and 140 days (mean, 87 days)
in three female monkeys (Noker and Gorman
2003b) compared with a more narrow range
for PFOS of 122–146 days (mean, 132 days)
and 88–138 days (mean, 110 days) for male
and female monkeys, respectively (Noker and
Gorman 2003a).
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